Comparative Pharmacology
Head-to-head clinical analysis: DILANTIN 30 versus OXCARBAZEPINE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DILANTIN 30 versus OXCARBAZEPINE.
DILANTIN-30 vs OXCARBAZEPINE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Stabilizes neuronal membranes by promoting sodium channel inactivation, thereby inhibiting repetitive firing of action potentials.
Stabilization of neuronal membranes by blockade of voltage-sensitive sodium channels, leading to inhibition of repetitive firing and reduction of neurotransmitter release.
300 mg/day orally in 3 divided doses (100 mg three times daily) or 300 mg/day once daily as an extended-release capsule. Loading dose: 1 g orally divided into three doses (400 mg, 300 mg, 300 mg) given at 2-hour intervals. Intravenous fosphenytoin loading dose: 15-20 mg PE/kg; maintenance: 4-6 mg PE/kg/day IV.
Initial 300 mg orally twice daily; increase by 300 mg/day every third day to target dose of 600-1200 mg/day in two divided doses. Maximum 2400 mg/day.
None Documented
None Documented
Clinical Note
moderateOxcarbazepine + Estrone sulfate
"The serum concentration of Estrone sulfate can be decreased when it is combined with Oxcarbazepine."
Clinical Note
moderateOxcarbazepine + Cobicistat
"The serum concentration of Cobicistat can be decreased when it is combined with Oxcarbazepine."
Clinical Note
moderateOxcarbazepine + Aripiprazole
"The serum concentration of Aripiprazole can be decreased when it is combined with Oxcarbazepine."
Clinical Note
moderateOxcarbazepine + Saxagliptin
Terminal elimination half-life averages 22 hours (range 7–42 hours) in adults; dose-dependent due to saturable metabolism (Michaelis-Menten kinetics). At low concentrations, half-life is approximately 10–15 hours; at high concentrations, half-life may exceed 30 hours. Clinical context: steady state achieved in 5–10 days; half-life prolonged in neonates, elderly, and hepatic impairment.
Oxcarbazepine: 2 hours (parent drug); MHD (active metabolite): 9 hours. Steady-state achieved in 2-3 days. Context: shorter t1/2 than carbamazepine; MHD t1/2 extended in renal impairment (up to 19 hours).
Renal: ~70% (primarily as inactive metabolites including p-HPPH glucuronide, with <5% unchanged); Biliary/fecal: ~30% (enterohepatic circulation contributes to biliary excretion of metabolites and a small amount of unchanged drug).
Renal: 70% (mainly as glucuronide metabolites, unchanged drug <1%). Fecal: negligible.
Category C
Category C
Anticonvulsant
Anticonvulsant
"The serum concentration of Saxagliptin can be decreased when it is combined with Oxcarbazepine."